Synthesis, antitumor activity evaluation and mechanistic study of novel Hederacolchiside A1 (cas 106577-39-3) derivatives bearing an aryl triazole moiety

Add time:08/01/2019    Source:sciencedirect.com

In an attempt to arrive at a more potent antitumor agent than the parent natural saponin hederacolchiside A1, 23 hederacolchiside A1 derivatives (4a-4w) were synthesized via Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition and screened in vitro for cytotoxicity against six human cancer cell lines. The structure-activity relationship of these compounds was elucidated, and the biological screening results showed that most of the compounds exhibited moderate to high levels of antitumor activities against the tested cell lines and some of them displayed more potent inhibitory activities compared with hederacolchiside A1. Compound 4f showed a 2- to 7-fold more potent activity than hederacolchiside A1. The mechanistic study of 4f revealed that this compound can induce cell apoptosis in HepG2 cells via mitochondrial-mediated intrinsic pathways.

We also recommend Trading Suppliers and Manufacturers of Hederacolchiside A1 (cas 106577-39-3). Pls Click Website Link as below: cas 106577-39-3 suppliers

Prev:Hederacolchiside A1 (cas 106577-39-3) suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway
Next:FT-IR, FT-Raman, UV/Vis spectra and fluorescence imaging studies on 2-(bromoacetyl)benzo(b)furan by ab initio DFT calculations)